Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis (Q30442932)

21 June 2017

1 reference

title

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis (English)

1 reference

21 June 2017

1 reference

Ronald P Taylor

1

1 reference

21 June 2017

Margaret A Lindorfer

series ordinal

2

1 reference

21 June 2017

publication date

1 February 2007

1 reference

Nature Clinical Practice Rheumatology

21 June 2017

published in

1 reference

21 June 2017

volume

3

1 reference

21 June 2017

issue

2

1 reference

21 June 2017

page(s)

86-95

1 reference

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

B cell-targeted therapy for rheumatoid arthritis: an update on the evidence

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

The biology of CD20 and its potential as a target for mAb therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Fc receptors and their role in immune regulation and autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Fcgamma receptors: old friends and new family members

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Fc receptors and their interaction with complement in autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Generation of C5a in the absence of C3: a new complement activation pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Evolving concepts of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcγ receptor I–directed immunotoxin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

The role of complement in the development of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

The immunopathology of joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Arthritis critically dependent on innate immune system players

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Development of proteoglycan-induced arthritis is critically dependent on Fcgamma receptor type III expression.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

The therapeutic potential of anti-CD20 "what do B-cells do?".

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Rituximab: perspective on single agent experience, and future directions in combination trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Studies of artificial cryoprecipitates containing anti-DNA antibody activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

C1q-binding immunoglobulin G in MRL/l mice consists of immune complexes containing antibodies to DNA

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0424

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0424

1 reference

21 June 2017

1 reference